Abbott Laboratories

Abbott operates globally with manufacturing, sourcing, and sales across the U.S. and international markets, and its results are meaningfully exposed to currency translation. In 2025, sales outside the United States represented approximately 61% of net sales, making foreign exchange movements a key driver of reported revenue and profitability. International operations can also be affected by local trade and investment rules, including import restrictions and exchange controls in certain countries. Abbott noted that Russia and Ukraine represent about 2% of total revenues and net assets, and while impacts have not been material to date, the region remains a monitored exposure.

Abbott’s performance depends on a large, complex global supply chain; disruptions (from pandemics, inflation, labor shortages, or logistics constraints) can raise costs or limit product availability. The business is heavily regulated across product development, manufacturing, labeling, promotion, and laboratory testing services, creating risk of delays, remediation costs, or restrictions following inspections or adverse events. Pricing and access are influenced by government reimbursement, tendering, and procurement programs (including volume-based programs in China), which can pressure net selling prices and volumes. With ~61% of sales outside the U.S., foreign exchange volatility and exchange controls can materially affect reported results, and cybersecurity incidents could disrupt operations or expose protected data; M&A (e.g., the pending Exact Sciences acquisition) adds integration and execution risk.